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Abstract 
Objective To compare changes over 48 weeks in body fat, lipids, Metabolic Syndrome and cardiovascular 
disease risk between patients randomised 1:1 to lopinavir/ritonavir (r/LPV) plus raltegravir (RAL) 
compared to r/LPV plus 2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTIs) as second-
line therapy. Methods Participants were HIV-1 positive (>16 years) failing first-line treatment (2 
consecutive HIV RNA >500 copies/mL) of NNRTI +2N(t)RTI. Whole body dual energy x-ray absorptiometry 
was performed at baseline and week 48. Data were obtained to calculate the Metabolic Syndrome and 
Framingham cardiovascular disease (CVD) risk score. Linear regression was used to compare mean 
differences between arms. Logistic regression compared incidence of metabolic syndrome. Associations 
between percent limb fat changes at 48 weeks with baseline variables were assessed by backward 
stepwise multivariate linear regression. Analyses were adjusted for gender, body mass index and smoking 
status. Results 210 participants were randomised. The mean (95% CI) increase in limb fat over 48 weeks 
was 15.7% (5.3, 25.9) or 0.9 kg (0.2, 1.5) in the r/LPV+N(t)RTI arm and 21.1% (11.1, 31,1) or 1.3 kg (0.7, 
1.9) in the r/LPV+RAL arm, with no significant difference between treatment arms (−5.4% [−0.4 kg], 
p>0.1). Increases in total body fat mass (kg) and trunk fat mass (kg) were also similar between groups. 
Total:HDL cholesterol ratio was significantly higher in the RAL arm (mean difference −0.4 (1.4); p = 0.03), 
there were no other differences in lipid parameters between treatment arms. There were no statistically 
significant differences in CVD risk or incidence of Metabolic Syndrome between the two treatment arms. 
The baseline predictors of increased limb fat were high viral load, high insulin and participant's not taking 
lipid lowering treatment. Conclusion In patients switching to second line therapy, r/LPV combined with 
RAL demonstrated similar improvements in limb fat as an N(t)RTI + r/LPV regimen, but a worse total:HDL 
cholesterol ratio over 48 weeks. 
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Abstract
Objective: To compare changes over 48 weeks in body fat, lipids, Metabolic Syndrome and cardiovascular disease risk
between patients randomised 1:1 to lopinavir/ritonavir (r/LPV) plus raltegravir (RAL) compared to r/LPV plus 2–3 nucleoside/
nucleotide reverse transcriptase inhibitors (N(t)RTIs) as second-line therapy.
Methods: Participants were HIV-1 positive (.16 years) failing first-line treatment (2 consecutive HIV RNA .500 copies/mL)
of NNRTI +2N(t)RTI. Whole body dual energy x-ray absorptiometry was performed at baseline and week 48. Data were
obtained to calculate the Metabolic Syndrome and Framingham cardiovascular disease (CVD) risk score. Linear regression
was used to compare mean differences between arms. Logistic regression compared incidence of metabolic syndrome.
Associations between percent limb fat changes at 48 weeks with baseline variables were assessed by backward stepwise
multivariate linear regression. Analyses were adjusted for gender, body mass index and smoking status.
Results: 210 participants were randomised. The mean (95% CI) increase in limb fat over 48 weeks was 15.7% (5.3, 25.9) or
0.9 kg (0.2, 1.5) in the r/LPV+N(t)RTI arm and 21.1% (11.1, 31,1) or 1.3 kg (0.7, 1.9) in the r/LPV+RAL arm, with no significant
difference between treatment arms (25.4% [20.4 kg], p.0.1). Increases in total body fat mass (kg) and trunk fat mass (kg)
were also similar between groups. Total:HDL cholesterol ratio was significantly higher in the RAL arm (mean difference 20.4
(1.4); p = 0.03), there were no other differences in lipid parameters between treatment arms. There were no statistically
significant differences in CVD risk or incidence of Metabolic Syndrome between the two treatment arms. The baseline
predictors of increased limb fat were high viral load, high insulin and participant’s not taking lipid lowering treatment.
Conclusion: In patients switching to second line therapy, r/LPV combined with RAL demonstrated similar improvements in
limb fat as an N(t)RTI + r/LPV regimen, but a worse total:HDL cholesterol ratio over 48 weeks.
Trial Registration: This clinical trial is registered on Clinicaltrials.gov, registry number NCT00931463 http://clinicaltrials.gov/
ct2/show/NCT00931463?term = NCT00931463&rank = 1.
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Introduction
HIV associated lipodystrophy is a syndrome of peripheral
lipoatrophy, central fat accumulation, and lipid derangement.
Lipodystrophy complicates the management of HIV-infected
patients through dyslipidaemia, increased cardiovascular disease
(CVD) risk and cosmetic affect. Both HIV infection itself and long
term exposure to combination antiretroviral therapy (cART) have
been implicated in the pathogenesis of lipodystrophy, which can
affect up to 50% of individuals receiving cART [1–4]. The use of
thymidine analogue nucleotide reverse transcriptase inhibitors (ta-
NRTIs) has been minimised in high-income countries, as they
have been implicated as the main cause of lipoatrophy and other
severe adverse events [1–8]. However, ta-NRTIs are still
commonly used as first-line treatment in low and middle-income
countries because of their comparatively low cost.
Changes in circulating lipoproteins have been demonstrated
with use of three of the major antiretroviral drug classes (protease
inhibitors [PI], nucleoside/nucleotide reverse transcriptase inhib-
itors [N(t)RTI] and non-nucleoside reverse transcriptase inhibitors
[NNRTI]), although the pattern of changes differ between and
among the three drug classes [5,9–13]. Recent clinical trials using
the integrase inhibitor, raltegravir (RAL), in antiretroviral naı̈ve
[14,15] and cART experienced participants [16,17] have reported
various effects on lipids. Results vary from reports of small
increases [14] to significant increases [15,16], whereas others
report improvements [17] in the lipid profile, compared to
N(t)RTIs, PIs or efavirenz. An in-vitro study has demonstrated RAL
had minimal affects on the expression of peroxisome proliferator
activated receptor (PPAR-c) and sterol regulatory element binding
protein (SREBP-1c), which are involved in lipid accumulation
[18]. Adipose tissue changes associated with RAL have also been
assessed in three small studies, which demonstrated no significant
change in body fat with RAL over 48 weeks compared to
N(t)RTI/PI based regimens [16,19] or comparable increases in
body fat to efavirenz [14]. More recently the larger PROGRESS
study 96 week results demonstrated lopinavir/ritonavir (r/LPV)
plus RAL increased peripheral fat, but not trunk fat compared to
r/LPV plus tenofovir/emtricitabine [20].
The Metabolic Syndrome is a condition characterised by the
clustering of alterations in glucose metabolism, lipid metabolism,
fat accumulation and blood pressure. Several studies have
reported a high prevalence of the Metabolic Syndrome in HIV
populations [21–24], which may be due to cART associated lipid
and adipose tissue disturbances. In one study, investigators
established that after initiation of cART the incidence of
Metabolic Syndrome was associated with significantly poorer
CVD outcomes [24]. The Metabolic Syndrome has been
identified as a significant risk factor for CVD by the U.S. National
Cholesterol Education Program Adult Treatment Panel III
(ATPIII) report [25,26]. To date the effects of RAL on the
Metabolic Syndrome compared to standard N(t)RTI/PI regimens
has not been investigated.
CVD accounts for 10% of deaths in patients with HIV infection
[27], which may be driven by HIV infection itself [28], lifestyle
factors [29,30] as well as cART [31–35]. There is a paucity of data
evaluating the effect of RAL on adverse cardiac outcomes. One
study conducted in healthy volunteers were given a suprather-
apeutic dose of RAL and demonstrated no prolongation of the QT
interval, i.e. ventricular repolarization [36]. In addition, the
PROGRESS study reported RAL did not significantly change the
CVD risk in patients over 48 weeks [15].
The Second-Line study provided a unique opportunity to
examine the lipodystrophy syndrome and CVD risk, using RAL +
r/LPV as an alternate N(t)RTI-sparing treatment option for
participants failing first-line NNRTI +2N(t)RTI. We hypothesised
that an N(t)RTI-sparing cART regimen containing RAL would
result in greater restoration of limb fat than combinations
containing N(t)RTI.
Materials and Methods
Design
The Second-line study is a 96 week, multinational trial of
participants failing first-line therapy, randomised 1:1 and stratified
by clinical site and screening plasma viral load (#100 000 copies
per mL or .100 000 copies per mL) to the World Health
Organization recommended second-line treatment (r/LPV+2–
3N(t)RTI) or r/LPV (400/100 mg bd or 800/200 mg qd)+ RAL
(400 mg bd). The randomisation sequence was computer gener-
ated with blocked randomisation (block size of four) and triggered
by the investigator entering all participant consent, screening, and
eligibility data. Allocation was concealed until interventions were
assigned, after which participants and investigators were not
masked to treatment. Eligible participants were HIV-1 positive
adults (aged $16 years) who had received first-line cART
comprised of an NNRTI+2N(t)RTIs for $24 weeks with no
change within 12 weeks prior to screening; evidence of virological
failure defined by 2 consecutive ($7 days apart) plasma HIV RNA
viral load .500 copies per mL; no previous exposure to PIs and/
or Integrase Strand Transfer Inhibitors. The study was approved
by each site’s Ethics Committee and was registered at Clinical-
trials.gov (NCT00931463). The cohort median (IQR) age was 38.5
(32.4–44.4) years, 55% male, 42% Asian and 36% African, 73%
heterosexual transmission, with an estimated duration of HIV
infection of 6.0 (3.6–8.7) years. The primary results of the Second
Line study have been described [37].
The protocol and analysis plan for this trial and supporting
CONSORT checklist are available as supporting information; see
CONSORT checklist (Checklist S1), Bone and Body Comp
Substudy protocol (Protocol S1), and SECONDLINE w48 bone
and body comp analysis plan (Analysis Plan S1). Of the 37 sites
that participated in the Second-Line study 8 sites from 5 countries
(South Africa, India, Malaysia, Thailand, Argentina) participated
in the body composition sub-study (clinicaltrials.gov identifier:
NCT01513122) and analysed as a subgroup of the parent Second-
Line study. These sites had access to a Dual energy X-ray
absorptiometry (DXA) scanner and recruitment was open to all
participants screened at these sites between July 2010 and July
2011. The sub-study was approved by each site’s Ethics
committee’s and all participants gave written, informed consent.
The specific ethic’s committee’s that gave approval for this sub-
study are: 1. YRG-CARE Institutional Review Board, Chennai,
India 2. Medical Ethics Committee, University of Malaya Medical
Centre, Kuala Lumpur, Malaysia 3. Kohn Kaen University
Institutional Review Board, Kohn Kaen, Thailand 4. University of
the Free State Ethics Committee, Bloemfontain, South Africa 5.
Institutional Review Board, Faculty of Medicine, Chulalongkorn
University, Bangkok, Thailand 6. Human Research Ethics
Committee, Faculty of Health Sciences, University of Cape Town,
Cape Town, South Africa 7. Human Research Ethics Committee
(Medical), University of the Witwatersrand, Johannesburg, South
Africa 8. Comite de Bioetica, CAEDI, Buenos Aires, Argentina.
DXA scans were performed at baseline and week 48 on either
Lunar (India n = 48, Malaysia n = 13, Argentina n = 8, Thailand
n = 22) or Hologic (Thailand n = 26, South Africa n = 94) DXA
scanners. Whole body composition was measured as per a
standard protocol provided to all sites. We did not use phantoms
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for quality assurance and scans were not subjected to central
interpretation, however scans were done on the same machine for
each participant and all imaging centres had quality control
measures in place.
The primary objective was to determine the difference in mean
limb fat changes (absolute and percentage change) as measured by
DXA scan between r/LPV+N(t)RTI and r/LPV+RAL arms from
baseline to 48 weeks. The secondary objectives included compar-
isons between treatment arms for mean change in total body fat
and trunk fat, distribution of limb fat percent change by treatment
arm, changes in lipid and glucose parameters, changes in 10 year
cardiovascular risk using the Framingham Equation [38], changes
in prevalence of the Metabolic Syndrome [39], and to explore the
relationship between limb fat mass and baseline variables.
Statistical Analysis
Analyses included all participants consented to the body
composition sub-study, who underwent randomisation, received
at least one dose of study medication and who completed both
week 0 and 48 DEXA scans. Results were considered statistically
significant at a two sided a= 0.05. A sample size of 100 per
randomised treatment arm was required to achieve 80% power to
detect a mean difference of 1 kg in limb fat.
At baseline there were imbalances between the two treatment
arms for gender, BMI and smoking status. All analyses were
adjusted for the imbalances in these covariates. Linear regression
was used to compare adjusted means of differences (baseline to
week 48) between randomised arms. Logistic regression was used
to compare the adjusted proportion of participants with Metabolic
Syndrome at week 48. Backward stepwise linear regression was
used to determine risk factors for limb fat change at week 48. Any
variables which were significant in univariate analyses with
p,0.10 were then included in multivariate analyses. The baseline
covariates considered were age, gender, ethnicity, body mass index
(BMI), smoking, blood pressure; concomitant medication (anti-
hypertensive medication, lipid-lowering therapy); HIV and anti-
retroviral therapy markers (randomised treatment arm, HIV
duration, CDC category, CD4+ and CD8+ lymphocyte counts,
duration of antiretroviral therapy (ART), use of ta-NRTI vs non-
thymidine NRTI, duration of ta-NRTI use; plasma HIV RNA);
body composition (total lean mass and limb fat); metabolic
markers (total cholesterol, high density lipoprotein (HDL) choles-
terol, low density lipoprotein (LDL) cholesterol, triglycerides, total
chol:HDL ratio); and glycaemic markers (glucose, insulin, and
homeostatis model assessment (HOMA) -calculated insulin sensi-
tivity). Age, gender and ethnicity remained in the multivariate
model regardless of the univariate results due to the confounding
influence of these parameters on limb fat.
Figure 1. Patient disposition of SECONDLINE body composition sub-study.
doi:10.1371/journal.pone.0077138.g001
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Table 1. Baseline Characteristics.
r/LPV +2–3N(t)RTI (n = 102) r/LPV + RAL (n = 108) Total (n = 210)
Age, years 38.6 (34.2–44.1) 38.9 (32.6–44.4) 38.8 (32.9–44.2)
Sex, male 55 (53.9) 45 (41.7) 100 (47.6)
Ethnicity
Caucasian 4 (3.9) 3 (2.8) 7 (3.3)
Asian 53 (52.0) 55 (50.9) 108 (51.4)
Hispanic 1 (1.0) 2 (1.9) 3 (1.4)
African 44 (43.1) 47 (43.5) 91 (43.3)
Unknown 0 1 (0.9) 1 (0.5))
Body Mass Index (BMI)
,18.5 18 (17.6) 13 (12.0) 31 (14.8)
18.5 to ,20 48 (47.1) 59 (54.6) 107 (51.0)
20 to ,30 26 (25.5) 24 (22.2) 50 (23.8)
30 to ,35 7 (6.9) 8 (7.4) 15 (7.1)
$35 3 (2.9) 4 (3.7) 7 (3.3)
Hip/Waist ratio 1.2 (1.1–1.2) 1.1 (1.1–1.2) 1.2 (1.1–1.2)
Blood Pressure (mmHg) 120/78 (109–126/70–81) 118/79 (109–129/70–83) 119/78 (109–128/70–82)
HIV RNA log10 (copies/mL) 4.3 (3.8–4.9) 4.1 (3.4–4.6) 4.1 (3.5–4.7)
Total fat mass (kg) 15.2 (8.3–22.1) 15.9 (10.0–23.8) 15.9 (8.8–22.7)
Total fat mass (%) 28 (15–35) 31 (18–40) 29 (18–39)
Total lean mass (kg) 40.3 (34.7–47.0) 40.8 (32.6–45.8) 40.6 (33.3–46.2)
Limb fat mass (kg) 6.3 (4.0–10.0) 7.4 (3.9–11.5) 6.9 (3.9–11.1)
Limb fat mass (%) 55 (20.3) 53 (19.6) 108 (20.0)
Glucose (mmol/L) 4.6 (4.3–5.1) 4.7 (4.3–5.1) 4.7 (4.3–5.1)
Total Cholesterol (mmol/L) 4.2 (3.6–5.0) 4.3 (3.8–4.9) 4.3 (3.8–5.0)
HDL Cholesterol (mmol/L) 1.1 (0.9–1.3) 1.1 (0.9–1.4) 1.1 (0.9–1.4)
Total cholesterol:HDL ratio 4.0 (3.2–5.0) 3.9 (2.9–4.7) 3.9 (3.0–4.8)
LDL Cholesterol (mmol/L) 2.5 (2.0–3.0) 2.6 (2.0–3.0) 2.5 (2.0–3.0)
Triglycerides (mmol/L) 1.3 (0.9–2.3) 1.3 (0.9–1.9) 1.3 (0.9–2.1)
Insulin (mu/L) 7.0 (4.6–11.9) 7.4 (4.5–14.0) 7.2 (4.5–13.5)
HOMA 1.4 (0.9–2.5) 1.6 (0.9–3.0) 1.5 (0.9–2.8)
Framingham CVD 10 year risk
Low (,10%) 94 (93.1) 101 (95.3) 195 (94.2)
Moderate (10–20%) 7 (6.9) 5 (4.7) 12 (5.8)
High (.20%) 0 0 0
Metabolic Syndrome n (%) 23 (22.5) 17 (15.7) 40 (19.0)
Smoking
Current 22 (21.6) 14 (13.0) 36 (17.1)
Recently (within 12mth) 1 (1.0) 2 (1.9) 3 (1.4)
Past 16 (15.7) 76 (70.4) 139 (66.2)
Never 63 (61.8) 52 (19.3) 87 (16.1)
Alcohol consumption
0–2 drinks per day 97 (95.1) 104 (96.3) 201 (95.7)
$2 drinks per day 5 (4.9) 4 (3.7) 9 (4.3)
History of diabetes 1 (1.0) 3 (2.8) 4 (1.9)
Family history of diabetes 20 (19.6) 25 (23.1) 45 (21.4)
On TDF 20 (19.6) 16 (14.8) 36 (17.1)
On d4T 50 (49.0) 51 (47.2) 101 (48.1)
On AZT 32 (31.4) 40 (37.0) 72 (34.3)
Duration AZT (years) 0.0 (0.0–2.1) 0.1 (0.0–2.3) 0.0 (0.0–2.2)
Duration d4T (years) 1.8 (0.0–3.4) 1.5 (0.0–3.8) 1.6 (0.0–3.6)
Data are median (IQR) or n (%); r/LPV: ritonavir boosted lopinavir; N(t)RTI: nucleoside reverse transcriptase inhibitor; RAL: raltegravir; TDF: tenofovir; d4T: stavudine; AZT:
zidovudine.
doi:10.1371/journal.pone.0077138.t001
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Results
Patient disposition is outlined in Figure 1. 699 participants were
screened for the parent study, of whom 236 consented to the body
composition sub-study. 211 participants were eligible and
randomised into the sub-study and 210 made up the analysis
population. 97 participants reached week 48 in the r/
LPV+N(t)RTI arm and 107 in the r/LPV+RAL arm.
Baseline characteristics of the sub-study cohort are described in
Table 1. The median age of the sub-study cohort was 38.8 years,
48% were male, 51% were Asian and 43% were African. At
baseline the median total body fat was 29% (18–39%) and limb fat
mass was 6.9 kg (3.9–11.1 kg). The median total cholesterol was
4.3 mmol/L (3.8–5.0 mmol/L), HDL cholesterol 1.1 mmol/L
(0.9–1.4 mmol/L), and triglycerides were 1.3 mmol/L (0.9–
2.1 mmol/L) at baseline. At baseline, 94% of the cohort were at
low (,10%) risk of 10 year cardiovascular disease, 6% were at
moderate risk and none had a high CVD risk. The prevalence of
Metabolic Syndrome at baseline was 19% for the cohort.
The primary objective results are outlined in Figure 2. Mean
limb fat (95% CI) increased over the 48 weeks by 15.7% (5.4 to
25.9%) or 0.9 kg (0.2 to 1.5 kg) in the r/LPV+N(t)RTI arm
compared with 21.1% (11.1 to 31.1%) or 1.3 kg (0.7 to 1.9) in the
r/LPV+RAL arm. The mean difference was 25.4% (213.7 to
2.9), p = 0.20.
The distribution of limb fat percent change by treatment arm is
outlined in Table 2. 32% and 19% of participants experienced no
increase in limb fat mass in the r/LPV+N(t)RTI and r/LPV+RAL
arms, respectively. By contrast, 29% and 40% of participants in
the r/LPV+N(t)RTI and r/LPV+RAL arms, respectively, had a
.20% gain in limb fat mass.
The total body and trunk fat mass increased in both treatment
arms. Participants in the r/LPV+N(t)RTI arm experienced a
mean (95% CI) increase in total body fat mass of 1.4 kg (0.2 to
2.7 kg) compared with changes in the r/LPV+RAL arm of 2.1 kg
(0.9 to 3.3 kg), p = 0.20. Trunk fat mass increased by 0.6 kg (20.1
to 1.2 kg) among recipients of r/LPV+N(t)RTI arm and by 0.8 kg
(0.1 to 1.4 kg) among recipients of r/LPV+RAL arm, p = 0.40.
The mean changes over time in lipid and glucose parameters
are summarised in Table 3. Triglycerides (r/LPV+N(t)RTI
0.6 mmol/L (0.3 to 0.9); r/LPV+RAL 0.8 (0.6 to 1.0) mean
(95% CI)) and total cholesterol (r/LPV+N(t)RTI 0.4 (0.1 to 0.6); r/
LPV+RAL 0.6 (0.4 to 0.9)) increased in both arms; however no
significant between group differences were found (triglycerides
20.2 mmol/L (20.6 to 0.2); p = 0.30; total cholesterol
20.3 mmol/L (20.6 to 0.1); p = 0.13). HDL cholesterol increased
in the r/LPV+N(t)RTI arm by 0.01 mmol/L (95% CI 20.1 to
Figure 2. Mean change in limb fat mass from week 0 to 48 by treatment arm.
doi:10.1371/journal.pone.0077138.g002
Table 2. The distribution of percent limb fat gain by treatment arm.
Limb fat gain categories r/LPV+2–3N(t)RTI (n = 94) r/LPV+RAL (n = 107) Total (n = 201)
#0% 30 (31.9) 20 (18.7) 50 (24.9)
0.1–10% 22 (23.4) 31 (29.0) 53 (26.4)
10.1–20% 15 (16.0) 13 (12.2) 28 (13.9)
.20% 27 (28.7) 43 (40.2) 70 (34.8)
Data are expressed as n (%).
doi:10.1371/journal.pone.0077138.t002
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0.1) but decreased in the r/LPV+RAL arm by 0.04 mmol/L
(20.1 to 0.0), with no significant differences between treatment
arms (0.05 (20.1 to 0.2); p = 0.32). Glucose decreased (r/
LPV+N(t)RTI 20.04 mmol/L (20.2 to 0.2); r/LPV+RAL 20.1
(20.4 to 0.1)) but insulin (r/LPV+N(t)RTI 0.9mU/L (20.5 to 2.3);
r/LPV+RAL 0.9 (20.6 to 2.5)) and HOMA (r/LPV+N(t)RTI 0.1
(20.2 to 0.5); r/LPV+RAL 0.1 (20.4 to 0.6) increased in both
arms, however no significant between group differences were
found (glucose 0.1 mmol/L (20.2 to 0.4); p = 0.60; insulin
20.1 mU/L (22.1 to 2.0); p = 0.95; HOMA 0.02 (20.6 to 0.6);
p = 0.93). The total:HDL cholesterol ratio increased to a
statistically significant degree in the r/LPV+RAL arm (change
over time 0.3 (0.1 to 0.6) r/LPV+N(t)RTI vs 0.7 (0.5 to 1.0) RAL
arm, difference 20.4 (20.8 to 20.04, p = 0.03).
The Metabolic Syndrome was assessed at baseline and week 48
in all sub-study participants. The proportion of participants with
this syndrome at baseline was 23% in the r/LPV+N(t)RTI arm
and 16% in the r/LPV+RAL arm. Throughout the study there
were 8 new cases of Metabolic Syndrome in the r/LPV+N(t)RTI
arm and 14 new cases in the r/LPV+RAL arm. There was no
statistically significant difference between the newly acquired
Metabolic Syndrome cases in each arm; OR (95% CI) 1.6 (0.6 to
4.0), p = 0.36.
The distribution of 10 year CVD risk categories for the sub-
study cohort are summarised in Table 4. The majority (90–95%)
of the cohort were at a low risk of experiencing a CVD event
within 10 years at both baseline and week 48. Four participants in
the r/LPV+N(t)RTI arm developed moderate risk of heart disease
by week 48, while 5 participants in the r/LPV+RAL arm
developed moderate risk and one participant developed high risk
of heart disease by week 48. The mean change (95% CI) over
48 weeks in 10 year Framingham cardiovascular risk was 20.27%
(21.1 to 0.5) in the r/LPV+N(t)RTI arm and 0.26% (20.5 to 1.1)
in the r/LPV+RAL arm, which was not statistically significantly
different between treatment arms, mean difference 20.52% (21.2
to 0.1), p = 0.12.
The baseline covariates that were included in the multivariate
regression are summarised in Table 5. The significant independent
baseline predictors of gain in limb fat over the 48 week study were
higher plasma HIV RNA (b 0.51, p = 0.0003) and higher insulin (b
0.06, p = 0.0012). Participants on lipid lowering therapy (b 21.68,
p = 0.0286) at baseline were more likely to experience a reduction
in limb fat.
Discussion
In this 210 participant sub-study of the Second-line trial we
have demonstrated that in patients failing first line treatment
comprising an NNRTI+2NtRTI, LPV/r plus RAL demonstrated
similar improvements in lipoatrophy and did not significantly
change CVD risk or the Metabolic Syndrome, compared to a
LPV/r plus N(t)RTI regimen over 48 weeks. However, LPV/r
plus RAL was associated with an increased total:HDL cholesterol
ratio, suggesting an adverse affect on the lipid profile.
The majority of previous studies examining soft tissue changes
associated with RAL treatment are limited by their small sample
size. The STARTMRK [14] study reported an increase in limb fat
of 18% and trunk fat 20% over 48 weeks with no further increases
up to 96 weeks in 86 cART naive patients randomised to RAL +
TDF/FTC fixed dose or efavirenz + TDF/FTC fixed dose, with
no difference between treatment arms. These data are similar to
the increase in fat mass reported in participants receiving RAL in
our Second-line sub-study; 21% limb fat gain and 22% trunk fat.
No change in body fat was reported in the SPIRAL-LIP sub-study
when 74 virologically controlled HIV patients were randomised to
either RAL or a PI [19] nor in the KITE study when 60
virologically controlled HIV patients were randomised to either
RAL or N(t)RTI regimen [16]. More recently the PROGRESS
study reported on 206 HIV ART naive patients randomised to
LPV/r plus RAL or LPV/r plus tenofovir/emtricitabine over
Table 3. Changes from baseline to week 48 of fasting lipids, insulin, glucose and HOMA by treatment arm.
Metabolic Parameter LPV/r+2–3N(t)RTI (n = 94) LPV/r+RAL (n = 105) P value
Total cholesterol (mmol/L) 0.3 (20.2, 0.8) 0.5 (20.2, 1.4) 0.27
HDL cholesterol (mmol/L) 0.0 (20.2, 0.2) 0.0 (20.2, 0.2) 0.52
LDL cholesterol (mmol/L) 0.1 (20.2, 0.6) 0.3 (20.2, 1.0) 0.17
Triglycerides (mmol/L) 0.3 (0.0, 1.1) 0.5 (0.1, 1.3) 0.12
Total/HDL cholesterol ratio 0.2 (20.4, 0.8) 0.6 (20.2, 1.3) 0.0209
Glucose (mmol/L) 20.1 (20.4, 0.4) 20.1 (20.4, 0.3) 0.97
Insulin (mU/L) 0.6 (21.6, 4.0) 1.1 (22.7, 4.8) 0.79
HOMA 0.1 (20.5, 0.8) 0.2 (20.6, 1.0) 0.65
Data are expressed as median (IQR).
doi:10.1371/journal.pone.0077138.t003
Table 4. 10 year Coronary Heart Disease Risk (Framingham
Equation) categories by treatment arm at baseline and 48
weeks.
Treatment arm
and Visit Coronary Heart Disease Risk
Low (,10%)
Moderate
(10–20%) High (.20%)
Baseline
r/LPV +2–3N(t)RTI 94 (93.1) 7 (6.9) 0
r/LPV + RAL 101 (95.3) 5 (4.7) 0
Week 48
r/LPV +2–3N(t)RTI 86 (90.6) 9 (9.5) 0
r/LPV + RAL 99 (92.5) 7 (6.5) 1 (0.9)
New Incidence at week 48
r/LPV +2–3N(t)RTI 0 4 (4.2) 0
r/LPV + RAL 0 5 (4.7) 1 (0.9)
Data are expressed as n (%).
doi:10.1371/journal.pone.0077138.t004
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96 weeks [20]. In this study participants randomised to the RAL
arm significantly increased limb fat, but not trunk fat [20]. The
reason for these differences may be explained by the different
study populations. The STARTMRK, PROGRESS and Second-
line trial participants were randomised with uncontrolled viral
replication, the first two being cART naive and the last failing first
line therapy, whereas SPIRAL-LIP and KITE patients were
virologically controlled at randomisation. In addition, our study
reported that high baseline viral load significantly predicted limb
fat gain. This may infer that the increase in limb fat in the Second-
line sub-study cohort was a ‘return to health’ after cART was
switched to obtain virological control, especially since both the
N(t)RTI arm and the N(t)RTI sparing arms experienced similar
increases in limb fat mass. The significantly greater increase in
peripheral fat reported in the PROGRESS, that was not found in
our Second-line sub-study may be due to the different length of
follow-up, 48 versus 96 weeks. Further sub-study analysis of the
96 week data is planned.
The Metabolic Syndrome was not significantly different over
time between r/LPV+2–3N(t)RTI and r/LPV+RAL within the
48 weeks of this study. Metabolic Syndrome was numerically more
prevalent in recipients of the r/LPV+RAL regimen compared to
r/LPV+2–3N(t)RTI arm, however this was not a significant
difference. Fat accumulation was seen in the limbs, trunk and over
the total body with both treatment arms. Glucose, insulin and
HOMA were similar between the groups, indicating that neither
regimen adversely affected insulin sensitivity. Previous reports
confirm this finding in that RAL has only mild affects (increase of
2 mg/dL) on glucose metabolism over 96 weeks [14]. Some lipid
abnormalities have been previously reported with RAL, generally
that RAL may cause an increase in total cholesterol and
triglycerides but have no affect on total:HDL cholesterol ratio
[15,16,37,40]. When compared to efavirenz and PIs, RAL has
been shown to have less effect on lipids [14,17]. In comparison to
the parent study total population [37], this sub-study did not
demonstrate a significantly greater increase in total cholesterol,
HDL, or LDL cholesterol with RAL; however it did find a
significantly greater increase in the total:HDL cholesterol ratio
compared with N(t)RTIs. This finding has not been reported
previously and may be the component of the Metabolic Syndrome
that caused the greater incidence in the RAL arm. This infers that
the small (non-significant) increase in total cholesterol in the RAL
arm was driven by a reduction in HDL cholesterol and an increase
in LDL cholesterol.
Table 5. Baseline predictors of change in limb fat mass over 48 weeks.
Univariate Multivariate
Limb Fat Change Limb Fat Change
Risk Factor (n = 201) N kg (95% CI) P value kg (95% CI) P value
Randomisation Arm
r/LPV +2–3N(t) RTI* 94
r/LPV + RAL 107 0.46 (20.06, 1.0) 0.0831 0.38 (20.1, 0.9) 0.14
Age+ 201 0.0057 (20.03, 0.04) 0.74 0.02 (20.02, 0.05) 0.37
Sex+
Male* 94
Female 107 0.32 (20.2, 0.8) 0.22 0.39 (20.2, 1.0) 0.22
Race+
Caucasian* 6
Asian 103 20.19 (21.2, 1.6) 20.07 (21.5, 1.4)
Hispanic 3 22.12 (24.7, 0.4) 21.73 (24.2, 0.8)
African Heritage 88 0.05 (21.2, 1.7) 0.19 0.12 (21.3, 1.6) 0.38
Body mass index (kg/m2) x 201 0.05 (20.0,0.1) 0.0335 0.05 (20.0,0.1) 0.13
Smokingx
Currently* 34
Recently 3 0.7 (20.9, 3.5) 1.02 (21.1, 3.2)
Past 32 20.05 (21.0, 0.9) 20.01 (21.0, 0.9)
Never 132 0.4 (20.3, 1.1) 0.33 20.01 (20.8, 0.8) 0.81
Glycaemic Markers
HOMA 197 20.002 (20.02, 0.2) 0.10 20.09 (20.3, 0.2) 0.49
Insulin (mU/L) 197 0.041 (0.006, 0.08) 0.0226 0.06 (0.0, 0.1) 0.0012
Lipid lowering Therapy
No* 195
Yes 6 21.31 (22.8, 0.2) 0.0891 21.68 (23.2, 20.2) 0.0286
Log(HIV-RNA copies/mL) 201 0.43 (0.2, 0.7) 0.0014 0.51 (0.2, 0.8) 0.0003
*reference group.
+age, gender and ethnicity remained in the multivariate model regardless of the univariate results due to the confounding influence of these parameters on limb fat.
xbody mass index and smoking were adjusted for due to baseline imbalance.
doi:10.1371/journal.pone.0077138.t005
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The reasons for the different lipid results in this sub-study cohort
compared to the parent study are unknown. There are some
demographic differences between the parent study and the sub-
study populations; one being the higher proportion of Asian and
Africans in the sub-study (42% Asian, 36% African in the parent
study vs 51% Asian, 43% African in the sub-study). Also, there was
a higher proportion of women in the sub-study (52% vs 45%, sub-
study vs parent study). Unfortunately, sub-analyses to investigate
an association between ethnicity and gender are limited due to the
small sample size of each sub-group and the small changes in lipid
fractions. Analysis to assess the changes in lipid fractions over a
longer period of time is needed to further investigate these cohort
and lipid differences. Further sub-study analysis of the 96 week
data is planned.
It is widely reported that there is a link between body fat mass,
lipid abnormalities and cardiovascular disease in both non-HIV
and HIV populations [25,26,41]. In this study limb fat mass
increased after one year of RAL + r/LPV treatment, but the
cholesterol ratio was worse. The finding that RAL has no major
effect on CVD risk has previously been reported in the 48 week
PROGRESS study [15]. This non-statistical CVD change in both
studies may have been affected by too small a sample size to
examine clinically significant changes in CVD risk. Larger and
more detailed cardiovascular investigations would be needed,
including assessment of cardiovascular biomarkers, to assess the
long term affect of RAL on CVD.
Development of lipoatrophy is known to be associated with high
HIV RNA [42]. In this sub-study it may also be true that patients
with a higher HIV RNA at baseline have greater limb fat gain
once their cART is switched and their viral load is controlled. The
association reported in this sub-study between high baseline insulin
and limb fat gain is interesting. The pathogenesis of insulin
resistance may be through ectopic lipid accumulation in muscle
and liver tissue, as well as by abnormalities in adipocytokine
physiology in HIV patients with lipodystrophy [43]. In addition
N(t)RTIs have been shown to cause insulin resistance, possibly
though an indirect effect via the adipose tissue changes caused by
N(t)RTIs [33]. Therefore, in this previously N(t)RTIs treated HIV
population those with some degree of insulin resistance at baseline
may gain limb fat to a greater degree because of the improvement
in insulin sensitivity. Further and longer term analyses are needed
to confirm this hypothesis, including thorough evaluation of
insulin resistance at baseline. The finding that participants taking
lipid lowering therapy at baseline were more likely to reduce limb
fat over 48 weeks may suggest there is a direct affect of the
concomitant medication on adipose tissue. Another reason may be
that participants with lipid abnormalities (albeit controlled) are
more likely to be previously exposed to ta-NRTIs and there is an
intricate relationship between ta-NRTIs and inhibition of mito-
chondrial DNA polymerase c with adipocytes.
This study was conducted primarily (94%) in an Asian (India,
Thailand, Malaysia) and African (South Africa) population. To
date there has been a paucity of data on body composition changes
within the HIV populations of these countries. There have been
two previous body composition studies reported in India, both
using bioelectrical impedance analysers [44,45]. These studies
reported an increase in total body fat of 1.5 to 1.8 kg after
6 months of initiating first-line cART. These figures are similar to
the results in our population which reported an increase in total
body fat of approximately 2 kg over 48 weeks. There have also
been two body composition studies reported in Thailand, using
DXA [46,47]. In both studies it was reported that limb fat
increased by only 0.4 to 0.6 kg over 48 weeks after switching ART
because of virological failure. One study in South Africa
conducted on 83 ART naive HIV women investigated soft tissue
changes using a DXA scanner and reported a total fat mass of
26 kg and trunk fat mass of 10 kg, which compares similarly with
our population results of 17 kg total fat mass and 9 kg trunk fat
mass. Therefore, the body composition data presented in this
Second-line sub-study helps strengthen the evidence base for
populations in which HIV infection is endemic and long-term co-
morbidities are becoming a larger part of patient management as
more cART are rolled out within the health systems.
In conclusion, this study suggests a switch to an N(t)RTI-sparing
cART regimen consisting of r/LPV plus RAL has a similar affect
on limb fat and cardiovascular disease risk compared with r/LPV
plus N(t)RTIs, but may worsen the lipid profile.
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